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Introduction
The use of opioids has increased significantly in the last decade. Concern for the
undertreatment of pain emerged in the mid-1990s, prompting providers to treat pain as a fifth
vital sign. The pharmaceutical industry marketed their products as having significantly less abuse
potential than reality. Prescriptions for pain medications soared with prescription opioids leading
the way. Prescription opioids became ubiquitous in medicine cabinets and reports of abuse rose.
Casually administered, illicit sale, theft, and doctor shopping became more common as reports of
overdose also rose. By 2010, the United States government was issuing strategies to combat the
opioid crisis.1
People from all demographics were affected by the opioid crisis, including pregnant
women and their fetuses. Use of opioids during pregnancy can lead to many complications,
including neonatal abstinence syndrome (NAS) which results when an infant suffers withdrawal
after cessation of gestational exposure to addictive substances like opioids. 2 Opioid agonist
therapy (OAT) has long been the recommended treatment of choice for pregnant women with
opioid use disorder (OUD).3 However, the use of opioids to combat the poor outcomes of opioids
seems counterproductive. This study aims to explore if the use of medically assisted withdrawal
and opioid detoxification are as effective as OAT in improving outcomes for fetuses born to
women who were addicted to opiates during pregnancy.

Background
Methadone

Methadone is a long-acting, high-affinity, full mu-opioid receptor agonist that prevents
withdrawal symptoms while limiting euphoric side effects. 3 The typical length of effect is 24
hours or longer. It is available as oral solution, tablet, or injectable solution.4
Methadone drug therapy is recommended to be initiated as early in the pregnancy as
possible to maximize fetal outcomes. Due to potential for serious side effects, hospitalization is
suggested during initiation. Unlike buprenorphine, there is no need for withdrawal symptoms
before starting therapy. The starting dose varies according to the symptoms of the patient;
however, the typical dose is 20 to 30 milligrams (mg). Incremental titration of 5 to 10 mg every
three hours may be performed as needed according to withdrawal symptoms on the first day. Day
two dosing is the equivalent of the sum of the previous day’s dosing. If withdrawal symptoms
are observed, the dose may be increased until no additional increases are needed to prevent
withdrawal. Stabilization may require a week or more with the possibility of continued dose
adjustment. Once stabilized, the patient may be discharged, and care is continued at outpatient
treatment centers.4
Methadone administration is tightly controlled. Opioid treatment programs manage the
daily dosing of methadone. Administration of the drug is conducted using the oral solution form
so it can be observed, and diversion or misuse can be minimized. Office setting or at-home
administration is not practiced.5 The physiological changes of pregnancy may require dose
adjustments which can be managed by addiction specialists at treatment centers. 3 Average
maintenance dosing is 120 mg per day with evidence indicating better outcomes for those who
are dosed at higher daily amounts.4 According to the American College of Obstetricians and
Gynecologists (ACOG), methadone dose has no correlation with incidence or duration of NAS.3

A significant portion of women enrolled in methadone programs continue to abuse
substances during pregnancy, requiring high index of suspicion for polysubstance use. Drug
monitoring is conducted by weekly urine drug testing. The urine drug screen-9 will test for
methadone and other naturally occurring opioids, but not synthetic opioids such as
buprenorphine or fentanyl which may need to be ordered separately. Index of suspicion for
polysubstance use should remain high due to its role in reducing the benefits of OAT and
increasing harm to the fetus.4
Buprenorphine
Buprenorphine is a partial mu-opioid receptor agonist that was approved for use in 2002.6
It has a high affinity for the receptor, meaning it binds stronger to but with lower activity than
full opioid agonists such as heroin, morphine, or methadone resulting in similar pharmacologic
effects but with a ceiling effect at high doses. This results in lowered risk of adverse side effects
such as respiratory depression, overdose, and death. Typical administration is done sublingually
or buccally due to greater bioavailability as compared to oral administration. 4 Buprenorphine is
available as a monoproduct or in combination with naloxone, an opioid antagonist that is used to
counteract symptoms of opioid overdose. The purpose of naloxone is to deter users from
injecting the drug in order to achieve a greater euphoric effect or diverting the drug so others can
do the same. Naloxone has no effect if taken sublingually, buccally, or orally but will have full
effect if injected. Concern for possible adverse side effects of naloxone on the fetus has
influenced discouragement of use of the combination product in pregnant patients5, however
recent guidance from ACOG has indicated that naloxone may have no adverse effects and may
be safe for use in pregnancy as time goes on and more data are collected. 3

Initiation of buprenorphine treatment may lead to withdrawal symptoms, particularly if
the patient has been exposed to opioids recently. It should be initiated when the patient shows
signs of moderate withdrawal: chills alternating with flushing or diaphoresis, nausea, yawning,
anorexia, lacrimation, rhinorrhea, or moderate muscle or joint aches. The effects of
buprenorphine last from 24 to 48 hours, resulting in once daily or every other day dosing. Initial
dosing is typically 2 to 4 mg with titration of an additional 2 to 8 mg after two hours of
observation if withdrawal symptoms persist. Day two dosing is the equivalent of the sum of the
previous day’s dosing. If withdrawal symptoms are observed, the dose may be increased in 4 mg
increments for a maximum daily dose of 16 mg. Dosing for the average patient stabilizes at 8 to
16 mg per day with possible need to adjust the dosing throughout pregnancy. 4 Due to its partial
agonist action, increasing the dose to more than 32 mg may not add to its efficacy. 7
Dispensation and monitoring of buprenorphine differ from methadone. Though
buprenorphine may be administered through opioid treatment programs like methadone, it can
also be dispensed through office-based means by trained U.S. Drug Enforcement
Administration-approved providers. Weekly or monthly prescriptions are possible.5 Monitoring
is conducted by urine drug testing with buprenorphine and/or its metabolite norbuprenorphine
specified on the order. Frequency determined clinically.4
Naltrexone
Naltrexone is an opioid antagonist. It competitively binds to opioid receptor sites with the
highest affinity for mu-opioid receptors, blocking the euphoric effects of opioids and reducing
craving which aid in abstinence efforts.8 Its forms include oral and injectable. The oral form has
demonstrated poor adherence with no efficacy over placebo. Intramuscular naltrexone is longacting and is effective for four weeks.9 Currently, there is limited research on the effects of

naltrexone on the fetus and pregnancy outcomes and guidance is to determine treatment on a
case by case basis. A woman currently on naltrexone should be counseled on the limited safety
data of the effects of naltrexone on the fetus if she chooses to continue treatment as well as the
risk of relapse if she chooses to discontinue treatment to pursue complete detoxification.3
Initiation of therapy requires an opioid-free period of at least seven to 10 days in order to avoid
full withdrawal upon administration of the drug, which could cause harm through fetal stress or
relapse.8
Opioid Detoxification
Neonatal abstinence syndrome is a big motivator for the use of opioid detoxification
during pregnancy. Successful detoxification results in no opiates in the mother’s system which
would prevent NAS from occurring after birth. This has been attempted through residential
treatment programs, incarceration, involuntary institutionalization, and individually without any
medical supervision.10 Rates of relapse are high with one study showing at 96% positive urine
toxicology at delivery as well as reports of postpartum maternal death due to overdose.10 Slow
tapering off opioid maintenance treatment (buprenorphine or methadone) during pregnancy to
reach complete detoxification has similarly shown relapse and the necessary return to some level
of the previous treatment.11 Though detoxification is attractive, it will most likely result in the
risk of NAS due to withdrawal.
Neonatal Abstinence Syndrome
Neonatal abstinence syndrome is a constellation of symptoms experienced by the
newborn while undergoing withdrawal due to the abrupt discontinuation of opioids upon birth.
Gestational exposure to such substances as methadone, buprenorphine, cocaine,

benzodiazepines, alcohol, nicotine, and other opioid-containing drugs like fentanyl,
hydrocodone, or oxycodone can result in NAS. Additionally, other factors may contribute to the
presentation of NAS such as polysubstance abuse, maternal psychiatric comorbidities, exposure
to violence and other maternal stressors, inadequate nutrition, and poor prenatal care.12 Though
rarely fatal, complications of NAS can cause illness and subsequent prolonged hospital stays.2
The clinical presentation of NAS can be varied. The infant may display emphasis of one
or a few symptoms with little or no expression of others, or they may display each symptom. The
specific symptoms include hyperirritability, excessive high-pitched crying, exaggerated Moro
reflex, myoclonic jerks, hypertonicity, tremors, poor sleep, uncoordinated sucking reflexes,
gastrointestinal disturbances, and autonomic disturbances such as fever, sweating, sneezing, and
yawning. Not all symptoms are immediately obvious. Infants whose symptoms are primarily
autonomic will be more subtle to detection and require more astute observation. In these cases,
diagnosis is further complicated by a less pronounced response to treatment. 12
Neonatal abstinence syndrome symptoms generally start within the first 72 hours of life
for infants exposed to methadone and last for several days to weeks. Infants exposed to
buprenorphine, NAS symptoms usually appear within 12 to 48 hours and last for seven days.
Currently, the modified Finnegan Scoring System is the most commonly used tool to diagnose
NAS. Neonates are observed for various central nervous, gastrointestinal, and autonomic
disturbances every three to four hours while awake after feeding. Typically, a score of above
eight is considered pathological and requires pharmacological treatment, however that score may
vary according to the institution.13 Diagnosis is clinical, but toxicological confirmation may be
necessary to rule in or out other substances that may have been present during pregnancy. This
may be done with meconium or urine testing.2

Treatment for NAS can be both pharmacological and nonpharmacological.
Nonpharmacological treatment consists of soothing techniques and manipulation of the
environment to calm the mother and infant.12 Transfer of methadone or buprenorphine into breast
milk is minimal regardless of dose, therefore breastfeeding is indicated for mothers who are
stable on their opioid agonist, are not abusing illicit or licit drugs, and are not infected with
human immunodeficiency virus (HIV). It has been associated with lowered severity of NAS
symptoms in infants, shorter hospital stays, and a lowered need for pharmacotherapy.3
Pharmacological treatment is indicated when signs and symptoms are not controlled,
severe dehydration results from withdrawal, serious side effects occur such as seizures, or
Finnegan scores remain high. The goal of treatment is to reduce severity of NAS symptoms to a
level that allows for the infant to eat, sleep, and interact.12 The most common agent used is
morphine. Its short half-life requires frequent dosing, but dose adjustment can be made quickly if
necessary. However, weaning must be done slowly. Hospital stays may be prolonged if morphine
is used. Methadone is another option. Unlike morphine, it is dosed twice daily due to its long
half-life, making it difficult to titrate. Buprenorphine is a newer alternative but lacks enough data
to support its use. Adjuvants include phenobarbital or clonidine.2

Methods
PubMed was searched between May 24, 2019 and July 22, 2019. Keywords included in
the search were: pregnancy, opioids, buprenorphine, methadone, naltrexone, detoxification,
neonatal abstinence syndrome, and OUD. Studies that were included were in English, contained
information pertaining to human studies, and focused on pregnant women using OAT or
detoxification and neonatal outcomes.

Discussion
Opioid Agonist Therapy Alternatives
Opioid detoxification is an option that is ideal in theory, but difficult to execute in
practice. The goal is to decrease the chances of NAS and therefore decreasing the lengths of
hospital stays and associated negative outcomes for the infant. Successful detoxification has been
linked to absence of NAS, higher birth weights in comparison to those with ongoing illicit drug
use, preterm birth rates and fetal loss comparable to the general population, and normal physical
development. However, the studies showing these outcomes had high variability with fair to poor
overall quality of evidence. Accurate interpretation of the data was limited due to the
retrospective studies and lack of randomized controls.12
NAS is a painful consequence of opioid use. It is painful for the neonate to suffer through
and witnessing can induce feelings of guilt and anxiety in the mother. This can lead to high rates
of relapse, which is harmful for the health of the mother as well as contribute to poor outcomes
for her infant. Relapse rates were high in most studies, resulting in continued gestational opioid
exposure and increased risk of HIV and hepatitis infection; some studies reported maternal death
due to overdose in the postpartum period. Behavioral therapy and ongoing support are crucial to
success throughout the perinatal and postpartum periods. In addition to high relapse rates, fetal
stress in response to maternal withdrawal has limited data but remains a high concern that should
be discussed with every potential candidate for detoxification. Current evidence indicates there is
not enough data to support detoxification as a superior option to OAT.12
Naltrexone, an opioid antagonist, is another alternative to OAT. It is not an opioid, thus
NAS and its associated neonatal outcomes such as low birth weight and extended hospital stays

are decreased in comparison to mothers treated with OAT if it is utilized faithfully. However, in
the study conducted by Kelty and Hulse, NAS was not eliminated. This was attributed to the
mother relapsing during pregnancy. The study did not find an association between naltrexone
and perinatal mortality or neonatal mortality. Rates of congenital birth abnormalities are
comparable to the general population; however, rates of urogenital abnormalities are higher.14
Given these positive outcomes, naltrexone seems a superior option, but consideration must be
given to the process of initiation of treatment. If the woman is not already on naltrexone at the
time of pregnancy, an opioid-free period of seven to 10 days is required, and she must exhibit
signs of withdrawal prior to initiation.8 This period is problematic for its high risk of relapse as
well as the limited data on the effect of maternal withdrawal on the fetus. Current naltrexone use
and the reliability of the woman must be heavily weighed when considering naltrexone as a
means of opioid avoidance maintenance during pregnancy. Attempts at detoxification should be
counseled against.3
Opioid Agonist Therapy
Methadone has been studied extensively and has been the medication of choice for opioid
addiction therapy for over 40 years. It has been shown to be highly effective in treating OUD and
has been recommended over detoxification due to the evidence of longer maternal abstinence,
higher compliance leading to lower rates of relapse and subsequent fetal illicit drug and
associated HIV and hepatitis exposure, and better neonatal outcomes.7 However, methadone use
is highly controlled, requiring its users to visit a treatment center daily and submit to frequent
urine monitoring. This may be beneficial to patients who require the rigid structure in order to
maintain discipline but may detract from compliance of those whose daily activities are
disrupted. Additionally, though it is a preferable alternative to heroin or fentanyl addiction,

methadone itself is an addictive opioid. Buprenorphine, being a partial mu-agonist that doesn’t
require the rigidity of methadone administration, can be a more attractive option.5
In addition to convenience, there are other factors to consider when comparing
methadone to buprenorphine. In most studies, both methadone- and buprenorphine-exposed
neonates exhibited NAS requiring pharmacological intervention. However, neonates exposed to
buprenorphine had lower incidences of NAS, required less medication and lower duration for
NAS as compared to neonates exposed to methadone.7, 15-18 In some studies that compared the
two maintenance agonist treatments, it was found that incidences of NAS was comparable
between buprenorphine and methadone, though there was no mention regarding severity or
duration of hospital stay. Regarding birth weights, those same review found that birth weights
were higher for neonates exposed to buprenorphine when compared to those exposed to
methadone.6, 19 As compared to women who used methadone for OAT, women on buprenorphine
were more likely to initiate OAT before or during early pregnancy, deliver at full term, have
longer rates of gestation, and deliver newborns with higher birth weight and bigger head
circumference.15
Though most studies showed better neonatal outcomes for neonates exposed to
buprenorphine, it should be noted that dropout and switch rates from buprenorphine to
methadone during treatment was higher than the reverse.6, 15, 19 The most cited reason was due to
suboptimal control of their withdrawal symptoms.15 Attrition rates for buprenorphine treatment
was generally higher than methadone treatment however, the data indicating reasons why is
limited as most studies did not track that information. It is an area worth additional research in
order to guide best practices for appropriate induction and maintenance dosing.7

Opioid agonist therapy during pregnancy, regardless of which medication is used, is an
important component of overall maternal, fetal, and neonatal health when compared to
uncontrolled opioid addiction during pregnancy. While buprenorphine has been shown in
multiple studies to be at least comparable, and in some cases superior, to methadone in terms of
neonatal outcomes, all studies concluded that both buprenorphine and methadone are important
components of treatment for opioid-dependent women at the time of pregnancy.3, 7, 15, 19
Limitations
Further research is needed in many areas. Information regarding the effects of maternal
withdrawal on the fetus would be invaluable in guiding treatment for those who wish to initiate
naltrexone treatment or detoxification but is very limited due to ethical constraints. Until that
data is gathered, non-opioid treatment during pregnancy will not be a viable option for most
mothers despite the superior neonatal outcomes as well as the fact that buprenorphine and
methadone have quickly become drugs of abuse themselves. The optimal dosing for
buprenorphine also needs to be studied further as attrition rates for buprenorphine treatment is
higher than those for methadone, but evidence indicates better neonatal outcomes for mothers
treated with buprenorphine over methadone. One factor that this study did not take into heavy
consideration was the multifaceted nature of low birth weights and its other possible
contributors, such as gestational age at birth, polysubstance abuse, cigarette smoking, and
alcohol use. However relevant, it was outside the scope of this paper. Lastly, the population of
affected children has grown due to the opioid epidemic, yielding an opportune time to study the
long-term effects of OAT. Some areas of interest may be behavioral, psychosocial, and pain
perception.
Treatment Recommendations

Recommendations on treating pregnant women who use opioids or have OUD place
heavy emphasis on screening. Early universal screening is highly advocated in order to both give
patients the care they need as well as to give options to women of reproductive age before they
become pregnant. Universal screening for every pregnant woman should also be conducted
regardless of their demographic or prior medical and social history to reduce stigma and avoid
missing cases. There are many recommended screening tools available such as CRAFFT (for
women 26 years or younger), 4Ps, NIDA Quick Screen.3
Opioid agonist therapy is the treatment of choice for pregnant women with OUD. The
outcomes are better for both mother and fetus. It is recommended over medically assisted
withdrawal or detoxification due to concerns over high relapse rates and the unknown effects of
withdrawal on the fetus. Behavioral therapy should also be initiated in conjunction with OAT
and extended into the postpartum period. During prenatal care, the clinician should expand
treatment to meet the special needs of both mother and fetus including additional fetal
monitoring to track fetal weight and development as well as additional maternal monitoring for
diseases common to substance abusers.3
Monitoring infants born to mothers who used opioids during pregnancy is important
given the possible subtle presentations of NAS. Infants should be monitored and treated by a
pediatric care provider. Breastfeeding should be encouraged if the mother is stable on OAT, not
abusing licit or illicit drugs, and have no other contraindications such as HIV infection.
Contraceptive counseling should be provided for any woman of reproductive age, particularly
those who abuse opioids or other drugs to avoid unintended pregnancy. Discussions should be
had prior to delivery regarding the possibility of long-term contraceptive devices such as an
intrauterine device which could be inserted immediately after delivery. 3

Conclusion
Opioid agonist therapy is the treatment of choice for pregnant women with OUD.
Neonatal outcomes are better with lower rates of NAS and higher birth weights as compared to
outcomes for neonates born to mothers with untreated OUD. Medically assisted withdrawal or
detoxification have high failure rates and put the mother and fetus at risk for continued
gestational opioid exposure and subsequent poor outcomes.
The guidelines that have been outlined can result in high rates of NAS, which can be
mentally and emotionally draining for all involved. Additionally, the concept of continuing to
give opioids to people who are addicted to opioids runs counter to intuition as well as the
precepts of some of the country’s most successful addiction recovery and support groups. 20 This
can influence people who are pregnant to insist on medically assisted withdrawal or
detoxification. It can also put heavy pressure on the provider to advise their patients of the same.
However, the data that were investigated for this study show that the nature of opioid addiction
can often overcome the nature of sheer willpower. Ultimately, NAS is more treatable than
overdose, severe fetal deformities, or fetal death. As a physician assistant, I will give healthy
respect to what this study has found and follow the guidelines issued by ACOG. I will advise my
prepartum and postpartum patients to consider medically assisted withdrawal or detoxification if
I have assessed that it is appropriate on a case-by-case basis.
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